NRX Pharmaceuticals Analyst Ratings
NRX Pharmaceuticals Analyst Ratings
While ratings are subjective and will change, the latest NRX Pharmaceuticals (NRXP) rating was a reiterated with a price target of $0.00 to $2.00. The current price NRX Pharmaceuticals (NRXP) is trading at is $1.22, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/02/2023 | 63.93% | HC Wainwright & Co. | → $2 | Reiterates | → Buy |
| 11/09/2022 | 227.87% | Ascendiant Capital | → $4 | Initiates Coverage On | → Buy |
| 06/30/2022 | 63.93% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变化 | 上一页/当前额定值 |
|---|---|---|---|---|---|
| 02/02/2023 | 63.93% | HC Wainwright & Co. | → 2 美元 | 重申 | → 购买 |
| 11/09/2022 | 227.87% | 上升资本 | → 4 美元 | 开启覆盖范围 | → 购买 |
| 06/30/2022 | 63.93% | HC Wainwright & Co. | → 2 美元 | 开启覆盖范围 | → 购买 |
What is the target price for NRX Pharmaceuticals (NRXP)?
NRX Pharmicals（NRXP）的目标价格是多少？
The latest price target for NRX Pharmaceuticals (NASDAQ: NRXP) was reported by HC Wainwright & Co. on February 2, 2023. The analyst firm set a price target for $2.00 expecting NRXP to rise to within 12 months (a possible 63.93% upside). 3 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年2月2日公布了NRX制药（纳斯达克股票代码：NRXP）的最新目标股价。这家分析公司将目标价定为2.00美元，预计NRXP将在12个月内升至2.00美元（可能上涨63.93％）。去年，有3家分析公司公布了评级。
What is the most recent analyst rating for NRX Pharmaceuticals (NRXP)?
NRX Pharmicals（NRXP）的最新分析师评级是多少？
The latest analyst rating for NRX Pharmaceuticals (NASDAQ: NRXP) was provided by HC Wainwright & Co., and NRX Pharmaceuticals reiterated their buy rating.
NRX Pharmicals（纳斯达克股票代码：NRXP）的最新分析师评级由HC Wainwright & Co.提供，NRX Pharmicals重申了买入评级。
When is the next analyst rating going to be posted or updated for NRX Pharmaceuticals (NRXP)?
NRX Pharmicals（NRXP）的下一个分析师评级将在何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NRX Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NRX Pharmaceuticals was filed on February 2, 2023 so you should expect the next rating to be made available sometime around February 2, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括浏览公开财务报表，与NRX Pharmicals的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月这样做一次，因此每家公司每年应该获得4次评级。NRX Pharmicals的最新评级是在2023年2月2日公布的，因此您应该预计下一个评级将在2024年2月2日左右公布。
Is the Analyst Rating NRX Pharmaceuticals (NRXP) correct?
分析师对NRX Pharmicals（NRXP）的评级是否正确？
While ratings are subjective and will change, the latest NRX Pharmaceuticals (NRXP) rating was a reiterated with a price target of $0.00 to $2.00. The current price NRX Pharmaceuticals (NRXP) is trading at is $1.22, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的NRX Pharmicals（NRXP）评级得到了重申，目标价为0.00美元至2.00美元。NRX Pharmicals（NRXP）目前的交易价格为1.22美元，在分析师的预测区间内。